ID

28344

Description

Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED); ODM derived from: https://clinicaltrials.gov/show/NCT00423150

Lien

https://clinicaltrials.gov/show/NCT00423150

Mots-clés

Versions (1)
  1. 05/01/2018 05/01/2018 -
Détendeur de droits

See clinicaltrials.gov

Téléchargé le

5 janvier 2018

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Colorectal Neoplasm NCT00423150

Anglais

Eligibility Colorectal Neoplasm NCT00423150

1 Formulaires  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
participants must be at least 18 years of age.
Description

Age

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
participants must have metastatic colorectal cancer (crc), recurrent or metastatic head & neck (h&n) or esophageal cancer, or locally advanced, inoperable, or metastatic non-small cell lung cancer (nsclc).
Description

Colorectal cancer metastatic | Recurrent Head and Neck Carcinoma | Head and neck cancer metastatic | Oesophageal carcinoma recurrent | Esophageal neoplasm metastatic | Non-Small Cell Lung Carcinoma Advanced Locally | Non-Small Cell Lung Carcinoma Inoperable | Non-small cell lung cancer metastatic

Type de données

boolean

Alias
UMLS CUI [1]
C0948380
UMLS CUI [2]
C1335703
UMLS CUI [3]
C0744619
UMLS CUI [4]
C0854761
UMLS CUI [5]
C0278562
UMLS CUI [6,1]
C0007131
UMLS CUI [6,2]
C0205179
UMLS CUI [6,3]
C1517927
UMLS CUI [7,1]
C0007131
UMLS CUI [7,2]
C0205187
UMLS CUI [8]
C0278987
participants must have a tumor sample or a blood sample tested positive for the presence of the biomarker.
Description

Tumor tissue sample Test Positive Biomarker | Blood specimen Test Positive Biomarker

Type de données

boolean

Alias
UMLS CUI [1,1]
C0475358
UMLS CUI [1,2]
C0022885
UMLS CUI [1,3]
C1514241
UMLS CUI [1,4]
C0005516
UMLS CUI [2,1]
C0178913
UMLS CUI [2,2]
C0022885
UMLS CUI [2,3]
C1514241
UMLS CUI [2,4]
C0005516
participants may have up to 3 prior regimens for crc, up to 3 prior regimens for nsclc, up to 2 prior regimens for h&n and esophageal cancer.
Description

Prior Therapy Quantity Colorectal Carcinoma | Prior Therapy Quantity Non-Small Cell Lung Carcinoma | Prior Therapy Quantity Cancer of Head and Neck | Prior Therapy Quantity Esophageal carcinoma

Type de données

boolean

Alias
UMLS CUI [1,1]
C1514463
UMLS CUI [1,2]
C1265611
UMLS CUI [1,3]
C0009402
UMLS CUI [2,1]
C1514463
UMLS CUI [2,2]
C1265611
UMLS CUI [2,3]
C0007131
UMLS CUI [3,1]
C1514463
UMLS CUI [3,2]
C1265611
UMLS CUI [3,3]
C0278996
UMLS CUI [4,1]
C1514463
UMLS CUI [4,2]
C1265611
UMLS CUI [4,3]
C0152018
participants must have at least one measurable lesion.
Description

Measurable lesion Quantity

Type de données

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1265611
participants must have an eastern cooperative oncology group (ecog) performance status of 0, 1, or 2.
Description

ECOG performance status

Type de données

boolean

Alias
UMLS CUI [1]
C1520224
participants must have adequate hematologic, renal, and liver functions.
Description

Hematologic function | Renal function | Liver function

Type de données

boolean

Alias
UMLS CUI [1]
C0221130
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232741
participants must be able to take the study medication capsules orally, or through a feeding tube without the capsules being opened.
Description

Able to swallow Oral Capsule | Intake Capsule Feeding tube

Type de données

boolean

Alias
UMLS CUI [1,1]
C2712086
UMLS CUI [1,2]
C0991533
UMLS CUI [2,1]
C1512806
UMLS CUI [2,2]
C0006935
UMLS CUI [2,3]
C2945625
participants of childbearing potential must agree to use a medically accepted method of contraception.
Description

Childbearing Potential Contraceptive methods

Type de données

boolean

Alias
UMLS CUI [1,1]
C3831118
UMLS CUI [1,2]
C0700589
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
participants who have received treatment for a second malignancy within 1 year before screening, and are considered to be at risk of relapse within 1 year after screening.
Description

Therapeutic procedure Second Cancer | At risk Recurrent disease

Type de données

boolean

Alias
UMLS CUI [1,1]
C0087111
UMLS CUI [1,2]
C0751623
UMLS CUI [2,1]
C1444641
UMLS CUI [2,2]
C0277556
participants with unstable or progressing central nervous system (cns) metastasis. participants with known cns metastasis may be included if a) the subject is asymptomatic, b) there is no requirement for steroids or antiseizure medications, or the required doses are stable, and c) there is no associated midline shift or (in the opinion of the investigator) significant edema.
Description

CNS metastases Unstable | CNS metastases Progressing | Exception Study Subject Asymptomatic | Exception Steroids Redundant | Exception Anticonvulsants Redundant | Exception Pharmaceutical Preparations Dosage Stable | Exception Midline Shift Absent | Exception Edema Absent

Type de données

boolean

Alias
UMLS CUI [1,1]
C0686377
UMLS CUI [1,2]
C0443343
UMLS CUI [2,1]
C0686377
UMLS CUI [2,2]
C0205329
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C0681850
UMLS CUI [3,3]
C0231221
UMLS CUI [4,1]
C1705847
UMLS CUI [4,2]
C0038317
UMLS CUI [4,3]
C1313915
UMLS CUI [5,1]
C1705847
UMLS CUI [5,2]
C0003286
UMLS CUI [5,3]
C1313915
UMLS CUI [6,1]
C1705847
UMLS CUI [6,2]
C0013227
UMLS CUI [6,3]
C0178602
UMLS CUI [6,4]
C0205360
UMLS CUI [7,1]
C1705847
UMLS CUI [7,2]
C4086580
UMLS CUI [7,3]
C0332197
UMLS CUI [8,1]
C1705847
UMLS CUI [8,2]
C0013604
UMLS CUI [8,3]
C0332197
participants who received prior temozolomide or dacarbazine treatment
Description

temozolomide | Dacarbazine

Type de données

boolean

Alias
UMLS CUI [1]
C0076080
UMLS CUI [2]
C0010927
Retour au début de la page

Similar models

Eligibility Colorectal Neoplasm NCT00423150

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
Age
Item
participants must be at least 18 years of age.
boolean
C0001779 (UMLS CUI [1])
Colorectal cancer metastatic | Recurrent Head and Neck Carcinoma | Head and neck cancer metastatic | Oesophageal carcinoma recurrent | Esophageal neoplasm metastatic | Non-Small Cell Lung Carcinoma Advanced Locally | Non-Small Cell Lung Carcinoma Inoperable | Non-small cell lung cancer metastatic
Item
participants must have metastatic colorectal cancer (crc), recurrent or metastatic head & neck (h&n) or esophageal cancer, or locally advanced, inoperable, or metastatic non-small cell lung cancer (nsclc).
boolean
C0948380 (UMLS CUI [1])
C1335703 (UMLS CUI [2])
C0744619 (UMLS CUI [3])
C0854761 (UMLS CUI [4])
C0278562 (UMLS CUI [5])
C0007131 (UMLS CUI [6,1])
C0205179 (UMLS CUI [6,2])
C1517927 (UMLS CUI [6,3])
C0007131 (UMLS CUI [7,1])
C0205187 (UMLS CUI [7,2])
C0278987 (UMLS CUI [8])
Tumor tissue sample Test Positive Biomarker | Blood specimen Test Positive Biomarker
Item
participants must have a tumor sample or a blood sample tested positive for the presence of the biomarker.
boolean
C0475358 (UMLS CUI [1,1])
C0022885 (UMLS CUI [1,2])
C1514241 (UMLS CUI [1,3])
C0005516 (UMLS CUI [1,4])
C0178913 (UMLS CUI [2,1])
C0022885 (UMLS CUI [2,2])
C1514241 (UMLS CUI [2,3])
C0005516 (UMLS CUI [2,4])
Prior Therapy Quantity Colorectal Carcinoma | Prior Therapy Quantity Non-Small Cell Lung Carcinoma | Prior Therapy Quantity Cancer of Head and Neck | Prior Therapy Quantity Esophageal carcinoma
Item
participants may have up to 3 prior regimens for crc, up to 3 prior regimens for nsclc, up to 2 prior regimens for h&n and esophageal cancer.
boolean
C1514463 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
C0009402 (UMLS CUI [1,3])
C1514463 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C0007131 (UMLS CUI [2,3])
C1514463 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
C0278996 (UMLS CUI [3,3])
C1514463 (UMLS CUI [4,1])
C1265611 (UMLS CUI [4,2])
C0152018 (UMLS CUI [4,3])
Measurable lesion Quantity
Item
participants must have at least one measurable lesion.
boolean
C1513041 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
ECOG performance status
Item
participants must have an eastern cooperative oncology group (ecog) performance status of 0, 1, or 2.
boolean
C1520224 (UMLS CUI [1])
Hematologic function | Renal function | Liver function
Item
participants must have adequate hematologic, renal, and liver functions.
boolean
C0221130 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
Able to swallow Oral Capsule | Intake Capsule Feeding tube
Item
participants must be able to take the study medication capsules orally, or through a feeding tube without the capsules being opened.
boolean
C2712086 (UMLS CUI [1,1])
C0991533 (UMLS CUI [1,2])
C1512806 (UMLS CUI [2,1])
C0006935 (UMLS CUI [2,2])
C2945625 (UMLS CUI [2,3])
Childbearing Potential Contraceptive methods
Item
participants of childbearing potential must agree to use a medically accepted method of contraception.
boolean
C3831118 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Item Group
C0680251 (UMLS CUI)
Therapeutic procedure Second Cancer | At risk Recurrent disease
Item
participants who have received treatment for a second malignancy within 1 year before screening, and are considered to be at risk of relapse within 1 year after screening.
boolean
C0087111 (UMLS CUI [1,1])
C0751623 (UMLS CUI [1,2])
C1444641 (UMLS CUI [2,1])
C0277556 (UMLS CUI [2,2])
CNS metastases Unstable | CNS metastases Progressing | Exception Study Subject Asymptomatic | Exception Steroids Redundant | Exception Anticonvulsants Redundant | Exception Pharmaceutical Preparations Dosage Stable | Exception Midline Shift Absent | Exception Edema Absent
Item
participants with unstable or progressing central nervous system (cns) metastasis. participants with known cns metastasis may be included if a) the subject is asymptomatic, b) there is no requirement for steroids or antiseizure medications, or the required doses are stable, and c) there is no associated midline shift or (in the opinion of the investigator) significant edema.
boolean
C0686377 (UMLS CUI [1,1])
C0443343 (UMLS CUI [1,2])
C0686377 (UMLS CUI [2,1])
C0205329 (UMLS CUI [2,2])
C1705847 (UMLS CUI [3,1])
C0681850 (UMLS CUI [3,2])
C0231221 (UMLS CUI [3,3])
C1705847 (UMLS CUI [4,1])
C0038317 (UMLS CUI [4,2])
C1313915 (UMLS CUI [4,3])
C1705847 (UMLS CUI [5,1])
C0003286 (UMLS CUI [5,2])
C1313915 (UMLS CUI [5,3])
C1705847 (UMLS CUI [6,1])
C0013227 (UMLS CUI [6,2])
C0178602 (UMLS CUI [6,3])
C0205360 (UMLS CUI [6,4])
C1705847 (UMLS CUI [7,1])
C4086580 (UMLS CUI [7,2])
C0332197 (UMLS CUI [7,3])
C1705847 (UMLS CUI [8,1])
C0013604 (UMLS CUI [8,2])
C0332197 (UMLS CUI [8,3])
temozolomide | Dacarbazine
Item
participants who received prior temozolomide or dacarbazine treatment
boolean
C0076080 (UMLS CUI [1])
C0010927 (UMLS CUI [2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial